William Blair Investment Management LLC Sells 647,615 Shares of Insmed, Inc. $INSM

Key Points

• William Blair Investment Management LLC reduced its stake in Insmed, Inc. by 28%, selling 647,615 shares, leaving them with approximately 1.67 million shares valued at $167.6 million.
• Analyst ratings for Insmed have generally been positive, with nineteen analysts
• Insmed reported a quarterly revenue of $107.42 million, exceeding expectations, although they posted a loss per share of ($1.70), missing analysts' estimates of ($1.30).

William Blair Investment Management LLC cut its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 28.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,665,602 shares of the biopharmaceutical company's stock after selling 647,615 shares during the period. William Blair Investment Management LLC owned 0.88% of Insmed worth $167,626,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. M&T Bank Corp raised its holdings in Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 147 shares during the period. ORG Partners LLC grew its holdings in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 196 shares during the period. Cullen Frost Bankers Inc. increased its position in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Insmed by 6.5% in the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock worth $287,000 after buying an additional 228 shares during the period. Finally, Hilltop National Bank bought a new position in shares of Insmed in the second quarter worth about $28,000.

Wall Street Analyst Weigh In

INSM has been the subject of a number of analyst reports. Morgan Stanley increased their price objective on shares of Insmed from $126.00 to $144.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Stifel Nicolaus lifted their target price on Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Guggenheim upped their price target on Insmed from $125.00 to $172.00 and gave the stock a "buy" rating in a research note on Monday, September 8th. Truist Financial lifted their price objective on shares of Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Finally, Wells Fargo & Company boosted their target price on shares of Insmed from $140.00 to $171.00 and gave the stock an "overweight" rating in a report on Wednesday, September 3rd. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $152.88.

Insmed Price Performance

INSM stock opened at $165.76 on Friday. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $166.44. The firm has a market capitalization of $35.04 billion, a P/E ratio of -29.03 and a beta of 1.03. The company has a fifty day simple moving average of $143.38 and a two-hundred day simple moving average of $104.83. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. During the same quarter in the prior year, the company posted ($1.94) earnings per share. The firm's quarterly revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, Director Melvin Md Sharoky sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director directly owned 262,675 shares of the company's stock, valued at $38,190,318.25. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the business's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.45, for a total value of $11,129,834.00. Following the transaction, the insider directly owned 36,461 shares in the company, valued at approximately $5,303,252.45. This represents a 67.73% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 211,057 shares of company stock valued at $27,438,126. Corporate insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.